Sort
261,768 grants matching “gene therapy”
Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer
$998,971Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2025 · CA
Novel therapy for Fragile X syndrome
$998,958Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2021 · MH
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease
$998,853Jennifer Joy Smith · Precyte, Inc. · R44 · FY2019 · AG
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease
$998,853Jennifer Joy Smith · Precyte, Inc. · R44 · FY2020 · AG
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2016 · HL
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2017 · HL
SAM-e Treatment of Depression in Parkinson's Disease
$998,754New York University School Of Medicine · R01 · FY2004 · AT
Protecting Pancreatic Islet Grafts from Rejection
$998,749Uwe D. Staerz · Isogenis, Inc. · R44 · FY2007 · DK
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome
$998,742Charles Andrew Stewart · Cartesian Therapeutics, Inc. · R44 · FY2021 · HL
Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias
$998,741Stephen F Betz · Crinetics Pharmaceuticals, Inc. · R44 · FY2018 · DK
GENE THERAPY STRATEGIES FOR SICKLE CELL DISEASE
$998,740University Of California San Francisco · P01 · FY2002 · HL
Tumor gene expression in vitro and in vivo
$998,705Douglas R. Lowy · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.
$998,648Michael King Schultz · Viewpoint Molecular Targeting, Inc. · R44 · FY2021 · CA
Optimization of a clinical stage nanoparticle drug delivery platform
$998,609Bob D. Brown · Dicerna Pharmaceuticals, Inc. · R44 · FY2017 · CA
Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation
$998,606William R Clarke · Xlock Biosciences, Llc · R44 · FY2023 · AR
Development of a first-in-class therapeutic for producing 'on-demand' voiding
$998,525Karl B Thor · Dignify Therapeutics, Llc · R44 · FY2019 · DK
Micro-Organospheres Drug Screen to Lead Care (MODEL): a Precision Oncology Platform to Guide Breast Cancer Therapy
$998,506Daniel Delubac · Xilis, Inc. · R44 · FY2023 · CA
Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine
$998,486Kenneth C Bagley · Profectus Biosciences, Inc. · R44 · FY2015 · AI
Spatial genomics analysis of tumor samples
$998,481Kirsten Frieda · Spatial Genomics, Inc. · R44 · FY2023 · CA
Spatial genomics analysis of tumor samples
$998,481Kirsten Frieda · Spatial Genomics, Inc. · R44 · FY2024 · CA
NEI Genetic Engineering Core
$998,433Lijin Dong · National Eye Institute · ZIC · FY2011 · EY
Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk
$998,385Ellen L. Goode · Mayo Clinic Rochester · R01 · FY2023 · CA
Antithrombotic Protein C Activator for Hemodialysis
$998,345Erik Ian Tucker · Aronora, Inc. · R44 · FY2021 · HL
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy
$998,324Irving Lerner Weissman · Stanford University · R35 · FY2022 · CA
A 3D vascularized islet biomimetic to model type 1 diabetes
$998,312Maike Sander · University Of California, San Diego · UH3 · FY2023 · DK